Who we are...

Accium BioSciences is the first commercial provider of Accelerator Mass Spectrometry (AMS) bioanalytical services in North America.

As a specialty CRO, we provide ultrasensitive quantitation of radiolabeled drugs and their metabolites in clinical samples with routine detection of less than 0.01 DPM in small biological samples.

Our GLP-compliant services enable attomole-level quantitation of drugs and metabolites in samples obtained from human mass balance, absolute bioavailability, microdosing, long-term PK and biotransformation/drug metabolism studies. 

These lightly-labeled (0.1 uCi) studies are performed at a number of qualified partner clinics.  Accium BioSciences also offers overall project and vendor management for these studies.

Our client list includes some of the top global pharmaceutical companies.  Approximately 60% of our current study pipeline is from our existing client base.

What we do...

Our laboratories...

Custom-Designed AMS Analytical Facility for Early Drug Development 

Accium BioSciences is the only accelerator mass spectrometry facility in the world to combine all aspects of  sample preparation, graphite preparation and AMS analysis under one roof.  The facility features a high throughput, custom designed 1.5 SDH-1 Pelletron Accelerator Mass Spectrometer dedicated to drug development services.  You can be assured of sample chain of custody, the quality of results and analytical throughput that is second to none at our GLP (Good Laboratory Practice) standard facility.

Our core expertise...

Recent News

Want To Learn More? 

Please call +1 (206) 281-3915 (8-5 PM PST) to learn more information about our AMS bioanalytical services.